🇺🇸 IOBENGUANE in United States

145 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Neutropenia — 36 reports (24.83%)
  2. Mucosal Inflammation — 33 reports (22.76%)
  3. Thrombocytopenia — 13 reports (8.97%)
  4. Product Use In Unapproved Indication — 12 reports (8.28%)
  5. Pyrexia — 11 reports (7.59%)
  6. Anaemia — 10 reports (6.9%)
  7. Febrile Neutropenia — 9 reports (6.21%)
  8. Haematotoxicity — 8 reports (5.52%)
  9. Myelodysplastic Syndrome — 7 reports (4.83%)
  10. Gastrointestinal Haemorrhage — 6 reports (4.14%)

Source database →

IOBENGUANE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is IOBENGUANE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for IOBENGUANE in United States?

Marketing authorisation holder not available in our data.